Skip to main content
S&P 5007,772.52-0.59%DOW51,031.92-0.95%NASDAQ27,383.37-0.78%BTC$83,130.00-3.69%ETH$2,557.96-5.85%GOLD$4,112.40-1.78%OIL$90.73+1.44%
Smart Investors Daily
SID Premium
RN

NASDAQ · RNAC

Cartesian Therapeutics, Inc.

Healthcare · Biotechnology

$6.75

Down-$0.05 (-0.74%)

Updated Oct 7, 2026, 1:48 PM

SID Score

3.4/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
222.59M
P/E ratio
-4.64
Dividend yield
0.00%
52-week range
$5.60 – $11.00
Volume
171.21K
Avg. volume
136.97K

Price performance · RNAC

RNAC price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 6, 2026

RNAC closed at $6.75 after 21 trading sessions, down 24.58% for the selected period.

Last close
$6.75
Period change
-24.58%
Period low
$6.75
Period high
$8.95
Daily close
View OHLC price history
RNAC OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 6, 2026$7.15$7.23$6.75$6.75171.21K
Oct 5, 2026$7.36$7.425$7.11$7.14226.26K
Oct 2, 2026$7.32$8.05$7.29$7.36200.38K
Oct 1, 2026$7.16$7.44$7.15$7.22175.76K
Sep 30, 2026$7.31$7.57$7.15$7.21166.94K
Sep 29, 2026$7.28$7.56$7.10$7.24158.05K
Sep 28, 2026$7.32$7.345$7.01$7.21109.17K
Sep 25, 2026$7.60$7.60$7.31$7.41158.64K
Sep 24, 2026$7.86$7.87$7.415$7.62205.77K
Sep 23, 2026$8.05$8.155$7.65$7.87117.05K
Sep 22, 2026$8.03$8.32$7.95$8.08161.75K
Sep 21, 2026$8.11$8.23$7.753$7.9461.36K
Sep 18, 2026$7.88$8.26$7.66$8.03211.66K
Sep 17, 2026$8.11$8.27$7.79$7.86164.46K
Sep 16, 2026$7.95$8.03$7.72$7.91118K
Sep 15, 2026$8.00$8.01$7.67$7.89113.27K
Sep 14, 2026$8.19$8.2619$7.955$8.04110.25K
Sep 11, 2026$8.59$8.88$8.18$8.19123.13K
Sep 10, 2026$8.53$8.53$8.25$8.43128.3K
Sep 9, 2026$8.94$9.1509$8.56$8.6994.17K
Sep 8, 2026$9.11$9.26$8.75$8.9561.39K

Latest RNAC news

The latest Smart Investors Daily articles mentioning RNAC.

Stock researchCompany · Overview

RNAC research

Overview

Company profile and research snapshot.

Company profile

Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$42.67
Implied upside
—
Analysts
—
RNAC recent ratings
DateFirmRatingTarget
Sep 30, 2026HC Wainwright & Co.Buy—
Sep 29, 2026NeedhamBuy—
Aug 18, 2026WedbushOutperform—
Jun 10, 2026WedbushOutperform—
Jun 9, 2026NeedhamBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Jan 14, 2026

Generalized Myasthenia Gravis Market Outlook Shows Strong Momentum During the Forecast Period (2025–2034) Driven by Novel Immunotherapies | DelveInsight

The generalized myasthenia gravis market in 7MM is expected to show positive growth during the forecast period (2025–2034), mainly driven by the anticipated launch of emerging therapies such as Descartes-08 (Cartesian Therapeutics), FABHALTA (iptacopan) (Novartis), Claseprubart (DNTH103) (Dianthus Therapeutics), and others, and the increasing incidence of gMG.New York, USA, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Generalized Myasthenia Gravis Market Outlook Shows Strong Momentum During the Forecast Pe

Yahoo · Jan 9, 2026

Cartesian Therapeutics Highlights Recent Progress and Outlines 2026 Outlook

Enrollment on track in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis IND application for Descartes-08 in myositis accepted by FDA; seamless adaptive clinical trial offering potential opportunity for a single pivotal trial expected to commence in 1H26 Phase 1/2 pediatric trial of Descartes-08 in juvenile dermatomyositis initiated Cash resources expected to support planned operations, including completion of planned Phase 3 trial for Descartes-08 for myasthenia gravis, into mid-2027 FR

Yahoo · Jan 6, 2026

Cartesian Therapeutics Announces New Employment Inducement Grants

FREDERICK, Md., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to two new employees. On January 2, 2026, the Company issued to these employees options to purchase an aggregate of 7,350 shares of the Company’s common stock with an exercise price of $6.76, the closing trading price of the Company’s common stock on

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By